[CLSTR]
API
< Back to all clusters
[HEALTH] · Denmark · 8 sources

started · updated

Part of situation: Genmab clinical trial developments (2 clusters)

Genmab petosemtamab combination reduces head and neck cancer death risk by 50%

Genmab petosemtamab head and neck cancer LiGeR-HN1 trial pembrolizumab

Genmab announced that its bispecific antibody petosemtamab, when used in combination with MSD’s Keytruda (pembrolizumab), met both primary endpoints in a Phase 3 trial for first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

In the LiGeR-HN1 trial, the combination therapy reduced the risk of death by 50% compared to pembrolizumab alone, according to an interim analysis by an independent data monitoring committee. The study also showed a statistically significant improvement in the objective response rate, with an odds ratio of 3.17.

The clinical benefits were observed regardless of human papillomavirus (HPV) status. The combination was reported to be generally well tolerated, with no new safety signals identified. Petosemtamab is an investigational IgG1 bispecific antibody that targets EGFR and LGR5.

Following these results, Genmab shares saw significant increases. The company plans to present full results at an upcoming medical meeting and engage with global regulatory authorities regarding the therapy.

Entities

Everett E. Vokes · FDA · Genmab · Genmab A/S · Incyte · Jan van de Winkel · Keytruda · MSD · Nasdaq · Pembrolizumab · Pembrolizumab · Petosemtamab

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

젠맙, ‘페토셈타맙·키트루다’ 두경부암 3상서 키트루다 대비 사망 위험 50%↓ [www.thebionews.net]
[미국 특징주] 젠맙 하루 28.25% 급등…두경부암 3상 두 지표 충족 [www.tokenpost.kr]
Tilray Brands Aktie: Jefferies legt einen Dollar drauf, rät ab [www.kapitalmarktexperten.de]
Genmab's $8B Merus bet passes Phase 3 test in head and neck cancer [european-biotechnology.com]
Genmab: Petosemtamab-Kombi trifft beide Phase-3-Endpunkte gegen Kopf-Hals-Krebs [www.it-boltwise.de]
Genmab drug halves death risk in head and neck cancer - NLS [nordiclifescience.org]
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC [www.cancernetwork.com]
Genmab Shares Jump 16% as Rally Builds on Cancer Drug Wins, JPMorgan Upgrade and Head and Neck Trial Hopes [www.ibtimes.com.au]